Ticho Barry, chief medical officer at Stoke Therapeutics (STOK), has been a consistent seller of company stock over the past year, with Form 4 filings showing 38 total transactions and zero open-market purchases. The aggregate value of sales reached roughly $1.72 million, all in STOK shares, with the most recent cluster of 18 sales occurring between December 2025 and July 2026. The selling pattern is steady rather than episodic: transactions appear on a near-monthly cadence, including sales on July 1, 2026, totaling about $236,000, and a June 1, 2026, sale of approximately $54,900.
The largest single dispositions came in mid-March 2026, when Barry sold shares worth roughly $191,000 on March 18 and another $117,000 on March 17, alongside smaller sales of $86,000 and $15,000 in the same window. Those sales were preceded by option exercises on March 15 with no reported dollar value, a mechanical event that typically provides the shares later sold. Earlier activity in December 2025 shows a similar rhythm: option exercises on December 3 followed by sales on December 2–5 ranging from roughly $10,000 to $62,000. A February 2026 grant of shares with zero value reflects compensation, not a purchase.
The data reveals a clear one-directional bias: every open-market transaction is a sale, with no buys recorded. The sales are modest in size relative to typical insider liquidations, rarely exceeding $200,000 in a single day, and they track closely with option exercises and equity grants. This pattern—recurring sales, no purchases, and values tied to compensation events—suggests routine portfolio diversification rather than a concentrated exit, though the absence of any buying activity over the entire filing period is notable for a senior officer.
AI-assisted summary